GBS diagnostic code from the state-wide hospital discharge database representing acute GBS was only 30%. Of the 103 confirmed cases, 26 (25%) would have been missed if only the state hospital discharge database was used to identify potential cases.

Of 103 cases, all were identified with ICD-9-CM diagnosis code 357.0; in 91 (88%) cases, this was the primary diagnosis. Other combinations of codes did not identify additional cases. Of cases of acute GBS identified, 32 (30%) met only clinical criteria (Brighton Level 1), 40 (39%) had either laboratory or electrophysiologic evidence (Brighton Level 2), and 32 (31%) had both (Brighton Level 3).

Because the 2 surveillance systems we compared both relied on medical record discharge diagnoses, they were not independent, and we could not perform a capture/recapture analysis. Because GBS is a diagnosis for which the great majority of patients are hospitalized, and our overall incidence rate is within the range identified in other studies, it is likely that the combination of these methods is reasonably sensitive. The administrative hospital discharge database could not be relied on to confirm that all coded GBS cases were acute. Even if the 114 nonacute cases could easily have been identified and excluded from the initial list of 344 records, only 103 (45%) of the remaining 230 reports were identified as confirmed acute cases.

Although the use of large hospital discharge databases may be useful as an adjunct for identification of GBS cases as part of public health surveillance, they lack sufficient sensitivity or specificity to be relied upon exclusively. The poor specificity of the system is particularly problematic for public health surveillance. A large investment of time and resources was necessary to perform manual chart reviews to confirm possible cases, two-thirds of which were ultimately found not to be cases at all. Statewide administrative hospital discharge diagnosis databases should not be solely relied on for GBS surveillance. Additional methods of reliable and efficient ascertainment and verification of cases are crucial to ensure valid data. Obtaining reliable methods is particularly important for urgent situations such as current surveillance for adverse events after pandemic (H1N1) 2009 virus vaccination, in which the detection of problems will have immediate public health effects.

Timothy F. Jones, Marcy McMillian, Effie Boothe, Samir Hanna, and L. Amanda Ingram
Author affiliation: Tennessee Department of Health, Nashville, Tennessee, USA
DOI: 10.3201/eid1609.091837

References

1. Centers for Disease Control and Prevention. Safety of influenza A (H1N1) 2009 monovalent vaccines—United States, October 1–November 24, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1–6.
2. Iskander J, Broder K. Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience. Expert Rev Vaccines. 2008;7:75–82. DOI: 10.1586/14760584.7.1.75
3. Iskander J, Haber P, Herrera G. Monitoring vaccine safety during an influenza pandemic. Yale J Biol Med. 2005;78:265–75.
4. Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, et al. Guillain-Barré syndrome following influenza vaccination. JAMA. 2004;292:2478–81. DOI: 10.1001/jama.292.20.2478
5. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939–50. DOI: 10.1016/S1474-4422(08)70215-1
6. McGrogon A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32:150–63. DOI: 10.1159/000184748
7. Mulloloy JP, Donahue JG, DeStefano F, Bags J, Eriksen E. Predictive value of ICD-9-CM codes used in vaccine safety research. Methods Inf Med. 2008;47:328–35.
8. Biel M, Glatting J, Zeller T, Kallen B, Mathieu M, et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med. 2004;158:1031–6. DOI: 10.1001/archpedi.158.11.1031
9. Bogliun G, Beghi E. Validity of hospital discharge diagnoses for public health surveillance of the Guillain-Barré syndrome. Neurol Sci. 2002;23:113–7. DOI: 10.1007/s10072000036
10. Sejvar J, Kohl KS, Gidud J, Amato A, Bakshe N, Baxter N, et al. Guillain-Barré syndrome and Fisher syndrome: case definition and guidelines for collection, analysis and presentation of immunization safety data. Atlanta: Centers for Disease Control and Prevention; 2009 [cited 2010 Apr 26]. http://www.brightoncollaboration.org

Address for correspondence: Timothy F. Jones, Tennessee Department of Health CEDS, 1st Floor, CHB 425 5th Ave N, Nashville, TN 37243, USA; email: tim.f.jones@tn.gov

LETTERS

Contact Lens Solution–associated Acanthamoeba and Fusarium Keratitis

To the Editor: Verani et al. (1) detailed the 2004–2007 outbreak of Acanthamoeba keratitis (AK) in persons wearing soft contact lenses who used Complete MoisturePlus (CMP) multipurpose contact lens solution (Advanced Medical Optics, Santa Ana, CA, USA). They noted similarities between the AK outbreak and the Fusarium keratitis (FK) outbreak of 2004–2006, including the concomitant time frame and association with a particular solution, ReNu with MoistureLoc (Bausch & Lomb, Rochester, NY, USA). Both solutions were new products introduced within 1 year before the respective outbreaks.

In neither outbreak was the solution contaminated; in both outbreaks,
implicated bottles were from multiple lots, suggesting that each outbreak resulted from insufficient antimicrobial activity. However, in the FK outbreak, all reported cases involved bottles produced at 1 (Greenville, SC, USA) of 4 multinational Bausch & Lomb manufacturing plants (2). After a Food and Drug Administration inspection of the Greenville facility, Bausch & Lomb was cited for inadequacies in temperature control during production, storage, and transport of its products in and beyond the plant (3).

We experimentally demonstrated that, when exposed to prolonged temperature elevation, ReNu with MoistureLoc loses more in vitro fungistatic activity than do other contact lens solutions. We concluded that improper temperature control of ReNu with MoistureLoc may have contributed to the FK outbreak (4). We are aware of no other theory that adequately explains why only ReNu with MoistureLoc from only 1 plant was implicated.

CMP was manufactured and used internationally; AK has a much higher incidence in Europe and Hong Kong than in the United States (5), and CMP–associated AK has been reported internationally (6). Therefore, it would seem critical to know, and we would like the authors to comment on, whether the geographic pattern of the AK coincided with distribution of CMP solution from ≥1 Advanced Medical Optics manufacturing plants and, if so, the relevance of that information.

John D. Bullock and Ronald E. Warwar

Author affiliations: Wright State University Boonshoft School of Medicine, Dayton, Ohio, USA

DOI: 10.3201/eid1609.091381

In Response: We thank Bullock and Warwar for offering their theory of potential consequences of manufacturing inadequacies in temperature control during production of ReNu with MoistureLoc (Bausch & Lomb, Rochester, NY, USA) associated with the Fusarium keratitis (FK) outbreak during 2004–2006 (1). They note the substantial similarities between the FK outbreak and the Acanthamoeba keratitis (AK) outbreak that we reported (2). They inquire whether the geographic pattern of AK outbreak–associated cases coincides with distribution of ≥1 manufacturing plants for the associated product, Complete MoisturePlus (CMP) multipurpose contact lens solution (Advanced Medical Optics [AMO], Santa Ana, CA, USA).

We obtained lot numbers for 22 bottles of CMP that AK case-patients used before symptom onset. Because no lot number was repeated, intrinsic contamination was unlikely as the source of the AK outbreak; the geographic and temporal distribution of cases further argued against a point-source outbreak. All 17 lot numbers for which AMO plant of origin was determined were manufactured in Spain (Food and Drug Administration, pers. comm.). According to a press release from AMO in November 2006, the “vast majority of AMO’s contact lens solution products distributed in the U.S.” were manufactured in the company’s production facility in Spain, 1 of its 2 international manufacturing plants (3).

CMP was produced and used internationally at the time of the US multistate outbreak (4). Por and colleagues (3) reported an increase in the number of AK cases among contact lens users in Singapore that temporally coincided with the US outbreak. However, their retrospective case series did not include a control group; therefore, measuring associations between particular contact lens products and AK was not possible for those case-
patients. The authors reported that a case–control study was underway, and we look forward to seeing the results of that investigation to better understand the magnitude of AK cases associated with CMP use.

Jennifer R. Verani, Jonathan S. Yoder, and Sharon L. Roy
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA
DOI: 10.3201/eid1609.100933

References
1. Bullock JD, Warwar RE. Contact lens solution-associated Acanthamoeba and Fusarium keratitis [letter]. Emerg Infect Dis. 2010;16:1501–2.
2. Verani JR, Lorick SA, Yoder JS, Beach MJ, Braden CR, Roberts JM, et al. National outbreak of Acanthamoeba keratitis associated with use of a contact lens solution, United States. Emerg Infect Dis. 2009;15:1236–42. DOI: 10.3201/eid1508.090225
3. US Food and Drug Administration. Advanced Medical Optics announces voluntary recall of 18 lots of Complete(R) MoisturePLUS(TM) contact lens care products distributed and sold in the U.S. Includes certain lots of 12-ounce bottles and active packs [cited 2010 Jun 11]. http://www.fda.gov/Safety/Recalls/ArchiveRecalls/2006/ucm112073.htm
4. US Food and Drug Administration. Advanced Medical Optics, Inc. COMPLETE® MoisturePLUS™ multi-purpose contact lens solution [2010 Jun 11]. http://www.fda.gov/MedicalDevices/Safety/Recalls/CorrectionsRemovals/ListingRecalls/ucm062478.htm
5. Por YM, Mehta JS, Chua JL, Koh TH, Khor WB, Fong AC, et al. Acanthamoeba keratitis associated with contact lens wear in Singapore. Am J Ophthalmol. 2009;148:7–12.e2. DOI: 10.1016/j.ajo.2009.02.030

New Infectious Diseases and Industrial Food Animal Production
To the Editor: Cutler et al. bring welcome attention to the importance of new and reemerging zoonotic diseases in the industrialized world (1). However, they make no mention of industrialized systems of food animal production, major sources of antimicrobial drug–resistant bacterial pathogens (2) that are among the most globally prevalent and emerging infectious diseases (3). These systems have practices characterized by crowded and unsanitary confinement of animals and routine use of antimicrobial agents in animal feeds (2). For example, in the same issue, Dutil et al. (3) reported on increases in cefitiofur resistance in Salmonella enterica isolates from food, which they associate with use of this drug in broiler poultry production.

Recognition of the role of industrial food animal production in driving vancomycin resistance in enterococci prompted restrictions on agricultural antimicrobial drug use in the European Union; unfortunately, few measures have been implemented in the rest of the world (including the United States) (4). Industrialized food animal production is now assumed to contribute to the emergence of new strains of community-associated methicillin-resistant Staphylococcus aureus (MRSA) in different animal species. Int J Med Microbiol. 2010;300:109–17. DOI: 10.1016/j.ijmm.2009.11.002

Address for correspondence: Ellen Silbergeld, Johns Hopkins School of Public Health—Department of Environmental Health Sciences, 615 N Wolfe St, Baltimore, MD 21205, USA; email: esilberg@jhsph.edu

Address for correspondence: Jennifer R. Verani, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop C23, Atlanta, GA 30333, USA; email: jverani@cdc.gov

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.

Author affiliations: Johns Hopkins School of Public Health, Baltimore, Maryland, USA (E. Silbergeld, M. Davis, B. Feingold, A. Goldberg, J. Leibler, A. Peterson); American Association for the Advancement of Science, Washington, DC, USA (J. Graham); and Center for Metagenomics and Human Health Translational Genomics Research Institute, Flagstaff, Arizona, USA (L.B. Price)
DOI: 10.3201/eid1609.100144

References
1. Cutler SJ, Fooks AR, van der Poel WHM. Public health threat of new, reemerging, and neglected zoonoses in the industrialized world. Emerg Infect Dis. 2010;16:1–7. DOI: 10.3201/eid1601.081467
2. Silbergeld EK, Graham J, Price L. Industrial food animal production, antimicrobial resistance, and human health. Annu Rev Public Health. 2008;29:151–69. DOI: 10.1146/annurev.publhealth.29.020907.09004
3. Dutil L, Irwin R, Finley R, Ng LK, Avery B, Boerin P, et al. Cefitiofur resistance in Salmonella enterica serovar Heidelberg from chicken meat and humans, Canada. Emerg Infect Dis. 2010;16:48–54. DOI: 10.3201/eid1601.090729
4. Nunnery J, Angulo FJ, Tollefson L. Public health and policy. Prev Vet Med. 2006;73:191–5. DOI: 10.1016/j.prevetmed.2005.09.014
5. Cuny C, Friedrich A, Kozytska S, Laver F, Nübel U, Ohslen K, et al. Emergence of methicillin-resistant Staphylococcus aureus (MRSA) in different animal species. Int J Med Microbiol. 2010;300:109–17. DOI: 10.1016/j.ijmm.2009.11.002

Address for correspondence: Ellen Silbergeld, Johns Hopkins School of Public Health—Department of Environmental Health Sciences, 615 N Wolfe St, Baltimore, MD 21205, USA; email: esilberg@jhsph.edu